Trial watch: dexmedetomidine in cancer therapy

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-03-11 DOI:10.1080/2162402x.2024.2327143

Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu

引用次数: 0

Abstract

Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviat...

查看原文本刊更多论文

试验观察：右美托咪定在癌症治疗中的应用

右美托咪定（DEX）是一种高度选择性的α2-肾上腺素受体激动剂，因其镇静和抗焦虑特性而被广泛应用于重症监护和麻醉护理中。它具有镇静和抗焦虑的特性，被广泛用于重症监护和麻醉护理中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.